scholarly journals Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

10.3791/54865 ◽  
2016 ◽  
Author(s):  
Ji-Eun Chang ◽  
Hyun-Jong Cho ◽  
Sanghoon Jheon
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Anticancer Efficacy ◽  
Targeted Nanoparticles

Photodynamic therapy in EGFR targeted nanoparticles for lung cancer

2016 ◽  
Vol 61 ◽  
pp. S144
Author(s):  
M. Laranjo ◽  
R. Teixo ◽  
A.M. Abrantes ◽  
A.C. Gonçalves ◽  
A.B. Sarmento Ribeiro ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Targeted Nanoparticles

Efficient synthesis and in vitro photodynamic anticancer study of new purpurinimide-hydrazone conjugates

2011 ◽  
Vol 15 (04) ◽  
pp. 264-270 ◽  
Author(s):  
Jia Zhu Li ◽  
Li Li ◽  
Jung Hwa Kim ◽  
Bing Cun Cui ◽  
Jin Jun Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Cell Lines ◽  
Efficient Synthesis ◽  
Lung Cancer Cell ◽  
Anticancer Activities ◽  
Anticancer Efficacy ◽  
A549 Lung Cancer Cell ◽  
A549 Lung

A series of new purpurinimide-hydrazone conjugates were synthesized, and their in vitro anticancer efficacy against A549 lung cancer cell lines was evaluated. It was found that the incorporation of the hydrazone group to the purpurinimide could increase their anticancer activities via a combination of photodynamic therapy and chemotherapy.

Endoscopic photodynamic therapy for Stage I lung cancer

1995 ◽  
Vol 16 (Supplement) ◽  
pp. 511-512
Author(s):  
Yoji Ishii ◽  
Michimaro Ejiri ◽  
Takuro Tsukube ◽  
Kiyoko Hirano ◽  
Sumio Nishi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Stage I ◽  
Stage I Lung Cancer

scholarly journals Artificial Cell-Mediated Photodynamic Therapy Enhanced Anticancer Efficacy through Combination of Tumor Disruption and Immune Response Stimulation

ACS Omega ◽  
2019 ◽  
Vol 4 (7) ◽  
pp. 12727-12735 ◽  
Author(s):  
Jiang Ni ◽  
Ying Sun ◽  
Jinfang Song ◽  
Yiqing Zhao ◽  
Qiufang Gao ◽  
...  
Keyword(s):  
Immune Response ◽  
Photodynamic Therapy ◽  
Anticancer Efficacy ◽  
Artificial Cell

scholarly journals SAFETY AND FEASIBILITY STUDY OF PHOTODYNAMIC THERAPY FOR ABLATION OF PERIPHERAL LUNG CANCER

CHEST Journal ◽  
2020 ◽  
Vol 157 (6) ◽  
pp. A239
Author(s):  
S. Bansal ◽  
R. Bechara ◽  
J. Patel ◽  
H. Mehta ◽  
J. Ferguson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Feasibility Study ◽  
Peripheral Lung Cancer ◽  
Peripheral Lung

Photodynamic therapy for intractable bronchial lung cancer

2013 ◽  
Vol 10 (4) ◽  
pp. 672-676 ◽  
Author(s):  
Xiao-jun Cai ◽  
Wen-min Li ◽  
Lan-ying Zhang ◽  
Xian-wei Wang ◽  
Rong-cheng Luo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy

scholarly journals Photodynamic Therapy of Lung Cancer With Bronchial Artery Infusion of Photofrin

1996 ◽  
Vol 2 (4) ◽  
pp. 203-206 ◽  
Author(s):  
Tetsuya Okunaka ◽  
Harubumi Kato ◽  
Chimori Konaka ◽  
Kinya Furukawa ◽  
Masahiko Harada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Early Stage ◽  
Bronchial Artery ◽  
Arterial Infusion ◽  
Early Stage Lung Cancer ◽  
Hospitalization Period ◽  
Bronchial Arterial Infusion ◽  
Skin Photosensitivity ◽  
Stage Lung Cancer

Photodynamic therapy (PDT) utilizing Photofrin is proving to be effective for the treatment of early stage lung cancer. However, wider clinical applications of Photofrin as a photosensitizer for various cancers are hampered by potentially serious and prolonged skin photosensitivity. To prevent these side effects and reduce the hospitalization period, we recently gave reduced doses of Photofrin by bronchial arterial infusion. Five patients with endoscopically evaluated minimally invasive carcinoma of the lung were given 0.7 mg/kg of Photofrin by bronchial arterial infusion 48 hr before PDT. Complete remission was obtained in all 5 cases and no case showed skin photosensitivity when exposed to sunlight under careful surveillance at one week after PDT.

scholarly journals Targeted Nanoparticles Harboring Jasmine-Oil-Entrapped Paclitaxel for Elimination of Lung Cancer Cells

2021 ◽  
Vol 22 (3) ◽  
pp. 1019
Author(s):  
Shira Engelberg ◽  
Yuexi Lin ◽  
Yehuda G. Assaraf ◽  
Yoav D. Livney
Keyword(s):  
Lung Cancer ◽  
Targeted Drug Delivery ◽  
A549 Cells ◽  
Average Diameter ◽  
Delivery Systems ◽  
Small Cell Lung ◽  
Targeted Nanoparticles ◽  
Ic50 Value ◽  
Residual Amount ◽  
Human Nsclc

Selectively targeted drug delivery systems are preferable chemotherapeutic platforms, as they specifically deliver the drug cargo into tumor cells, while minimizing untoward toxic effects. However, these delivery systems suffer from insufficient encapsulation efficiency (EE), encapsulation capacity (EC), and premature drug release. Herein, we coencapsulated paclitaxel (PTX) and Jasmine oil (JO) within PEG-PCL nanoparticles (NPs), with an average diameter < 50 nm, selectively targeted to non-small cell lung cancer (NSCLC) cells, via S15-aptamer (APT) decoration. JO was selected as an “adhesive” oily core to enhance PTX entrapment, as JO and PTX share similar hydrophobicity and terpenoid structure. JO markedly enhanced EE of PTX from 23% to 87.8% and EC from 35 ± 6 to 74 ± 8 µg PTX/mg PEG-PCL. JO also markedly increased the residual amount of PTX after 69 h, from 18.3% to 65%. Moreover, PTX cytotoxicity against human NSCLC A549 cells was significantly enhanced due to the co-encapsulation with JO; the IC50 value for PTX encapsulated within JO-containing APT-NPs was 20-fold lower than that for APT-NPs lacking JO. Remarkably, JO-containing APT-NPs displayed a 6-fold more potent cell-killing, relatively to the free-drug. Collectively, these findings reveal a marked synergistic contribution of JO to the cytotoxic activity of APT-NP-based systems, for targeted PTX delivery against NSCLC, which may be readily applied to various hydrophobic chemotherapeutics.

Sign in / Sign up

Export Citation Format

Share Document